FDG PET/CT与骨髓活检在儿童淋巴瘤中的预测价值比较
该回顾性研究纳入140例病理证实的儿童淋巴瘤患者(113例霍奇金病,27例非霍奇金淋巴瘤),所有患者治疗前接受FDG PET/CT,并收集骨髓活检(BMB)及随访数据。FDG PET/CT对骨髓浸润的阴性预测值为100%,BMB为80.2%(P < 0.05);PET/CT阳性预测值为95.1%,BMB为100%。基于5点评分的骨髓浸润肿瘤负荷与治疗结局无显著差异(P = 0.06)。
要点
- FDG PET/CT阴性预测值100%,BMB为80.2%(P < 0.05)。
- BMB漏诊25例(17.9%)骨髓浸润患者,PET/CT均检出。
- FDG PET/CT使17.9%患者分期上调。
核心结论
- FDG PET/CT在儿童淋巴瘤骨髓浸润检测中具有最佳阴性预测值,可检出BMB漏诊的病例并使17.9%患者分期上调。
- 基于5点评分的骨髓浸润肿瘤负荷对预后的主要影响在于浸润存在与否而非负荷大小。
研究设计与样本
- 回顾性研究纳入140例病理证实的儿童淋巴瘤患者(113例霍奇金病,27例非霍奇金淋巴瘤),所有患者有治疗前FDG PET/CT及骨髓活检、临床、影像和随访数据。
- 骨骼分为8个节段,采用5点评分系统评估骨髓浸润负荷。
主要发现
- 140例中FDG PET/CT示41例骨髓阳性,其中2例为假阳性(BMB及区域MRI阴性)。
- FDG PET/CT阳性预测值95.1%,BMB为100%。
- BMB诊断阳性骨髓浸润的患者均被FDG PET/CT检出;BMB漏诊25例(17.9%),差异有统计学意义。
- FDG PET/CT阴性预测值100%,BMB为80.2%(P < 0.05)。
- FDG PET/CT使17.9%入组患者分期上调。
关键数值与推荐
- 阳性预测值:FDG PET/CT 95.1% vs BMB 100%。
- 阴性预测值:FDG PET/CT 100% vs BMB 80.2%(P < 0.05)。
- BMB漏诊率17.9%(25例),FDG PET/CT分期上调率17.9%。
- 5点评分:局灶性(评分2)vs 广泛性(评分5)骨髓浸润的治疗结局P = 0.06。
临床怎么用
- 在儿童淋巴瘤骨髓浸润检测中,FDG PET/CT较BMB具有更高的阴性预测值,可检出BMB漏诊的骨髓浸润。
- FDG PET/CT可导致部分患者分期上调。
- 基于5点评分的骨髓浸润肿瘤负荷与治疗结局的关系仍需进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to explore the positive predictive value and negative predictive value of FDG PET/CT. The prognostic impact of tumor burden of bone marrow infiltrates was diagnosed by FDG PET/CT at initial presentation. METHODS: This retrospective study enrolled 140 pediatric patients with pathologically proven lymphoma (113 Hodgkin disease and 27 Non-Hodgkin lymphoma). All patients had pretherapy FDG PET/CT. Bone marrow biopsy (BMB), clinical, radiological, and follow-up data were also collected. The skeleton was divided into 8 segments, and a 5-point scoring system was used for assessment of BM infiltration burden. RESULTS: Among the 140 lymphoma patients, FDG PET/CT revealed positive BM involvement in 41 patients; 2 of them were false-positive with negative BMB and regional MRI results. Positive predictive value was 95.1% for PET/CT compared with 100% with BMB. All patients diagnosed with positive BMI by BMB were detected by FDG PET/CT. On the contrary, BMB missed 25 patients (17.9%) with statistically significant difference. Negative predictive value was 100% for PET/CT compared with 80.2% for BMB (P < 0.05). FDG PET/CT upstaged 17.9% of the enrolled patients. Bone marrow involvement based on the 5-point scoring system was assessed. No significant difference was demonstrated in therapy outcome between patient with focal BMI (score 2) and extensive BMI (score 5; P = 0.06). CONCLUSIONS: FDG PET/CT has optimum negative predictive value compared with BMB in detection of bone marrow infiltrations in pediatric lymphoma with upstaging cases missed with BMB. Prognostic impact of BMI based on the 5-point scoring system reveals that the main influence is presence or absence of BMI rather than its tumor burden.
引用
- Badr S, Kotb M, Elahmadawy MA, et al. Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma. Clin Nucl Med. 2018. PMID: 30358625. doi:10.1097/RLU.0000000000002315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。